Monitor the Q1 earnings call for confirmation of preliminary results and commentary on the CCO departure; the modest guidance lift may not offset decelerating sequential revenue.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 9 $1.53entry
- T+1 · 7mo ago +18.30%α +18.36% · $1.81
- T+5 · 7mo ago +22.22%α +19.04% · $1.87
- T+20 · 7mo ago +26.14%α +18.58% · $1.93
- T+60 · 4mo ago +198.04%α +187.26% · $4.56
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Treace Medical Concepts issued a preliminary Q1 2026 outlook showing revenue of $47.0–47.2M and cash rising to $51.9M, while updating full-year 2026 revenue guidance to $202–212M. The Chief Commercial Officer departed and will transition to a consulting role, with responsibilities absorbed internally.
Key Financial Metrics
Key Facts
- Preliminary Q1 2026 revenue: $47.0–47.2 million
- Cash, cash equivalents, and marketable securities expected to be ~$51.9 million as of March 31, 2026, up from $48.4 million at year-end
- Updated full-year 2026 revenue guidance raised to $202–212 million (from $200–212 million)
- Chief Commercial Officer Gaetano Guglielmino departed; no replacement planned; responsibilities reassigned
- Guglielmino to serve as consultant through January 31, 2027, receiving $36,666.67/month and other benefits
Financial Impact
Revenue guidance increase of $2M at midpoint; preliminary Q1 revenue implies sequential decline from Q4 2025's $62.5M
Risk Factors
- Preliminary Q1 revenue suggests a sequential decline from Q4 2025 ($62.5M), indicating potential weakening demand
- Departure of Chief Commercial Officer without replacement raises questions about commercial strategy execution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001630627-26-000010 |
| Document: 0001630627-26-000010-index-headers.html | 0001630627-26-000010 |
| Document: 0001630627-26-000010-index.html | 0001630627-26-000010 |
| Document: 0001630627-26-000010.txt | 0001630627-26-000010 |
| 8-K Data (Synthetic) | 0001630627-26-000010 |
Track record
11 reports on TMCI
2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +12.39% at T+60 after the Jul 13, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 16, 20261d ago SC 13G Neutral 4/10 Entry $4.42 to $4.44 Now $4.44 +0.45% ▲ +0.45% +1.47% vs SPY
- Nov 16, 20261d ago SC 13G/A Bearish 4/10 Entry $4.42 to $4.44 Now $4.44 −0.45% ▼ −0.45% −1.47% vs SPY
- Nov 12, 20266d ago Court Ruling Neutral 4/10 Entry $5.27 to $4.42 Now $4.44 −15.75% ▼ −16.13% −14.22% vs SPY
- Nov 6, 202611d ago 8-K Neutral 4/10 Entry $4.03 to $4.78 Now $4.44 +10.17% ▲ +18.61% +16.24% vs SPY
- Sep 17, 20268w ago Press Release Neutral 4/10 Entry $4.49 to $4.48 Now $4.44 −1.11% ▼ −0.22% −1.77% vs SPY
- Aug 7, 202614w ago 8-K Mixed 6/10 Entry $4.76 to $4.67 Now $4.44 −6.72% ▼ −1.89% −1.86% vs SPY
- Jul 13, 202618w ago Court Ruling Bearish 5/10 Entry $4.44 to $4.40 Now $4.44 −0.00% ▲ +0.90% +1.30% vs SPY
- May 8, 202627w ago Press Release Bearish 7/10 Entry $2.01 to $1.94 Now $4.44 −120.90% ▲ +3.48% +3.71% vs SPY
- Apr 24, 202629w ago Press Release Neutral 1/10 Entry $1.98 to $1.92 Now $4.44 +124.24% ▼ −3.03% −3.19% vs SPY
- Apr 9, 202631w ago 8-K Mixed 6/10 Viewing Entry $1.53 to $1.81 Now $4.44 +190.20% ▲ +18.30% +18.36% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers